Osteogenesis Imperfecta?

You or someone you know may be eligible to participate in the LINK Clinical Trial

The **LINK** Study aims to find out what impact the investigational medication has on the participant's bone mineral density and the frequency of fractures in children and adolescents with OSTEOGENESIS IMPERFECTA.

Children and adolescents may be eligible to participate in the LINK Study, provided the following criteria are met:*

- Be between **2 to 17** years of age (inclusive)
- Have been diagnosed with Osteogenesis Imperfecta (OI) Type I – IV
- Have a specific fracture history (to be discussed with/determined by your doctor)

* *There are other eligibility requirements that the study doctor will review with you. Only the study doctor can determine whether an individual is eligible for the study or not.*

Global / UK screening & enrollment update (as of 17Feb2017)

- Total global patients planned: 150 / Total UK patients planned: 10
- Total global patients enrolled: 23 / Total UK patients enrolled: 4

UK participating sites & Email contact detail

- Sheffield Children´s Hospital, Principal investigator: Prof Nick Bishop
  Study Coordinator contact Email kate.jones@sch.nhs.uk
- Birmingham Children´s Hospital, Principal investigator: Dr Nick Shaw
  Study Coordinator contact Email: wendy.donoghue@bch.nhs.uk
- Bristol Royal Hospital for Children, Principal investigator: Dr Christine Burren
  Study Coordinator contact Email: Rachel.helyer@uhbristol.nhs.uk
- Royal Hospital for Children, Glasgow, Principal investigator: Prof Faisal Ahmed
  Study Coordinator contact Email: barry.milligan@ggc.scot.nhs.uk

LINK study is sponsored by Amgen Inc.
023_AMG_20130173_FlyerBBS_v1.0

UKIE-NPC-162-0117-043961
12January2017